Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Issue 2 (10th July 2014)

• Record Type: Journal Article
• Authors: Cortesi, P. A.; Ciaccio, A.; Rota, M.; Lim, J. K.; De Salvia, S.; Okolicsanyi, S.; Vinci, M.; Belli, L. S.; Mantovani, L. G.; Strazzabosco, M.
• Is Part Of: Journal of viral hepatitis. Volume 22:Issue 2(2015)
• Page Start: 173
• Page End: 181
• Publication Date: 2014-07-10
• Subjects: Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12278
• Languages: English
• ISSNs: 1352-0504

Abstract

<abstract abstract-type="main" id="jvh12278-abs-0001"> <title>Summary</title> <p>New and more promising therapies for chronic hepatitis C (CHC) genotype 1 (G1) naive patients have recently been approved in the United States and Europe, and several more regimens are expected to become available within the next several years. While this scenario unfolds, it is necessary to develop a rational method to allocate current treatment in CHC G1 patients. We performed a cost‐effectiveness analysis of boceprevir (BOC)‐ and telaprevir (TVR)‐based triple therapy according to different patients' selection strategies. A semi‐Markov model of CHC natural history and progression towards end‐stage liver disease was built. We considered 3 selection strategies based on METAVIR fibrosis stage: (i) treat all patients with F1–F4 fibrosis, (ii) only F2–F4 and (iii) only F3–F4. For each strategy, TVR interleukin‐28B‐guided (IL28B‐guided) and BOC rapid virologic response‐guided (RVR‐guided) therapies were applied. The model assessed the costs and outcomes, using a lifetime and 5‐year time horizon, and adopting the Italian National Health System perspective. The incremental cost‐effectiveness ratio (ICER) for F1–F4 strategy relative to F3–F4 was €5132 per quality‐adjusted life years gained, across TVR IL‐28B‐guided therapy, and €7042 in the BOC RVR‐guided therapy. Conversely, in the 5‐year scenario, the ICER for F1–F4 strategy relative to F3–F4 was €1 818 679 (TVR IL28B‐guided) and €1 866 437 (BOC RVR‐guided) per end‐stage liver disease or death (ESLD‐D) avoided. In view of anticipated improvement in the efficacy of future regimens, selective treatment of only patients with advanced fibrosis and cirrhosis with TVR or BOC could represent the most cost‐effective strategy to optimize resource utilization.</p> </abstract>